Abstract
Triple nucleoside reverse transcriptase inhibitors are recommended as an alternative regimen for HIV-infected patients undergoing tuberculosis treatment in resource-limited settings. Few data exist on the efficacy of such regimens in tuberculosis patients. In 34 tuberculosis/HIV-co-infected patients treated with zidovudine/lamivudine/abacavir, 76% achieved HIV RNA less than 50 copies/ml at 24 weeks. No cases of hypersensitivity or immune reconstitution syndrome were observed. These data support the continuing evaluation of nucleoside-based antiretroviral regimens as an alternative treatment for this population.
MeSH terms
-
Adult
-
Antitubercular Agents / therapeutic use
-
CD4 Lymphocyte Count
-
Dideoxynucleosides / adverse effects
-
Dideoxynucleosides / therapeutic use*
-
Drug Hypersensitivity / etiology
-
Drug Therapy, Combination
-
Female
-
HIV Infections / complications
-
HIV Infections / drug therapy*
-
HIV Infections / immunology
-
Humans
-
Lamivudine / adverse effects
-
Lamivudine / therapeutic use*
-
Male
-
Middle Aged
-
Neutropenia / chemically induced
-
RNA, Viral / analysis
-
Reverse Transcriptase Inhibitors / adverse effects
-
Reverse Transcriptase Inhibitors / therapeutic use*
-
Treatment Outcome
-
Tuberculosis, Pulmonary / complications
-
Tuberculosis, Pulmonary / drug therapy*
-
Tuberculosis, Pulmonary / immunology
-
Zidovudine / adverse effects
-
Zidovudine / therapeutic use*
Substances
-
Antitubercular Agents
-
Dideoxynucleosides
-
RNA, Viral
-
Reverse Transcriptase Inhibitors
-
Lamivudine
-
Zidovudine
-
abacavir